3MV-28568-36548
3 vaccinations
5 coded responses
31 check-ins
4 free-text entries
1 call case
- Sex
- Male
- Age at first dose
- 0-4
- ZIP prefix
- 540 / WI
- Registered
- 2022-07-01
- Relationship
- Child or adolescent in my care
- Guardian
- JJL-30762-66567
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-07-01
Registered in v-safe
-
2022-07-01
Dose 1 — Pfizer-BioNTechCo-administered: Hepatitis A
-
2022-07-01
Health check-in — day 0, dose 1, under 3Feeling: Fair · Sleepiness, Irritability/cryingUnder 3 check-in
- 2022-07-02
- 2022-07-03
- 2022-07-04
-
2022-07-07
Health check-in — days 1–6 daily, dose 1, under 3Feeling: Good · Rash, not including the immediate area around the injection siteUnder 3 check-in
-
2022-07-07
Health check-in — days 1–6 daily, dose 1, dependentFeeling: Good · Rash, not including the immediate area around the injection siteAdult check-in
- 2022-07-08
- 2022-07-15
-
2022-07-22
Dose 2 — Pfizer-BioNTech
- 2022-07-22
- 2022-07-23
- 2022-07-24
- 2022-07-25
- 2022-07-26
- 2022-07-29
- 2022-08-05
- 2022-08-12
- 2022-08-19
- 2022-08-26
- 2022-09-02
-
2022-10-21
Survey response — 3 months, dose 2, under 3MedDRA: Asthma, Dyspnoea, Emotional distress, Respiratory rate increased, Sleep disorder, Use of accessory respiratory muscles, Wheezing — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visitFree text: shortness of breath, wheezing, retractions, rapid breathing, waking up screaming, heavy breathing, inconsolable (treated as asthma)MedDRA releases: 2024-11 · check-in free text available
-
2022-10-21
Report sent to call center — 3 months, dose 2, under 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · Emergency room or emergency department visit · 1 call case(s)
- 2022-10-24
-
2022-10-31
Dose 3 — Pfizer-BioNTechCo-administered: Flu
-
2022-11-03
Survey response — days 1–6 daily, dose 3, under 3MedDRA: Cough, Nasopharyngitis — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Symptoms of a Cold -coughingMedDRA releases: 2024-11 · check-in free text available
-
2022-11-05
Survey response — days 1–6 daily, dose 3, under 3MedDRA: Cough — Feeling: Poor · Fever · Loss of appetite · Be unable to do your normal daily activitiesFree text: CoughMedDRA releases: 2024-11 · check-in free text available
-
2022-11-06
Survey response — days 1–6 daily, dose 3, under 3MedDRA: Cough — Feeling: FairFree text: CoughMedDRA releases: 2024-11 · check-in free text available
- 2022-11-07
- 2022-11-16
- 2022-11-21
- 2022-11-28
- 2022-12-05
- 2022-12-12
- 2023-01-30
-
2023-05-03
Survey response — 6 months, dose 3, under 3MedDRA: Cough, Irritability, Malaise, Nasopharyngitis, Rhinorrhoea, SARS-CoV-2 test positive — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-07-01 | Pfizer-BioNTech | Hepatitis A |
| 2 | 2022-07-22 | Pfizer-BioNTech | No |
| 3 | 2022-10-31 | Pfizer-BioNTech | Flu |
Call center
1 call center case
1 unsuccessful
Free text
Release 12 (Under 3) — 3 months, dose 2, under 3
Symptoms: shortness of breath, wheezing, retractions, rapid breathing, waking up screaming, heavy breathing, inconsolable (treated as asthma)
Release 12 (Under 3) — days 1–6 daily, dose 3, under 3
Systemic reaction (other): Symptoms of a Cold -coughing
Systemic reaction (other): Cough
Systemic reaction (other): Cough
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Asthma | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Emotional distress | · | · | ✓ |
| SD | Irritability | · | · | ✓ |
| SD | Malaise | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Respiratory rate increased | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SD | Sleep disorder | · | · | ✓ |
| SD | Use of accessory respiratory muscles | · | · | ✓ |
| SD | Wheezing | · | · | ✓ |
| SRO | Cough | · | · | ✓ |
| SRO | Nasopharyngitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release